-
Study aim
-
The safety and effectiveness of labor induction with 25 micrograms of misoprostol compared to 50 micrograms of misoprostol in women with premature rupture of membranes are investigated.
According to the study results, a specific protocol for the delivery room of Shahid Akbarabadi Hospital will be developed.
-
Design
-
Patients are divided into two groups by easy sampling method.
-
Settings and conduct
-
Pregnant women referred to Shahid Akbarabadi Hospital who have full-term singleton pregnancies are included in the study from the beginning of 2022 to 2023. After confirming premature rupture of fetal membranes, in the absence of contraindications for natural delivery and contraindications for misoprostol administration, they will be placed in one of the two treatment groups of 25 micrograms and 50 micrograms of oral Misoprostol.
-
Participants/Inclusion and exclusion criteria
-
36 weeks pregnancy or more.
Premature rupture of the membranes is confirmed by the amniotic fluid method or clear discharge.
Bishop scores less than 4.
Live singleton pregnancy.
Parity less than 5.
No history of cesarean delivery.
Cephalic presentation.
Absence of contraindications for natural childbirth.
Absence of contraindications for prescribing misoprostol.
-
Intervention groups
-
Patients are divided into two groups, the first group receives 25 micrograms of oral misoprostol every 2 hours up to 12 doses and the second group receives 50 micrograms of oral misoprostol every 4 hours up to 6 doses.
-
Main outcome variables
-
The rate of occurrence of vaginal delivery, instrumental delivery, and cesarean delivery, the interval from induction of labor to birth, the incidence rate of chorioamnionitis, uterine tachysystole, amniotic fluid infection, neonatal outcomes including newborn Apgar score, intensive care unit admission, newborn death, need for antibiotic prescription and umbilical cord blood gases